GR3021892T3 - Stabilized vitamin D preparation - Google Patents

Stabilized vitamin D preparation

Info

Publication number
GR3021892T3
GR3021892T3 GR960403313T GR960403313T GR3021892T3 GR 3021892 T3 GR3021892 T3 GR 3021892T3 GR 960403313 T GR960403313 T GR 960403313T GR 960403313 T GR960403313 T GR 960403313T GR 3021892 T3 GR3021892 T3 GR 3021892T3
Authority
GR
Greece
Prior art keywords
active compound
pharmaceutical composition
heat
vitamin
preparation
Prior art date
Application number
GR960403313T
Other languages
English (en)
Inventor
Hiroki Itoh
Tetsuro Tabata
Jun-Ichi Kikuta
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of GR3021892T3 publication Critical patent/GR3021892T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GR960403313T 1991-04-09 1996-12-04 Stabilized vitamin D preparation GR3021892T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP7621091 1991-04-09
JP1909992 1992-02-04

Publications (1)

Publication Number Publication Date
GR3021892T3 true GR3021892T3 (en) 1997-03-31

Family

ID=26355908

Family Applications (1)

Application Number Title Priority Date Filing Date
GR960403313T GR3021892T3 (en) 1991-04-09 1996-12-04 Stabilized vitamin D preparation

Country Status (14)

Country Link
US (1) US5487900A (el)
EP (1) EP0508756B1 (el)
JP (1) JPH05279260A (el)
KR (1) KR100231633B1 (el)
AT (1) ATE144424T1 (el)
AU (1) AU649802B2 (el)
CA (1) CA2065603C (el)
DE (1) DE69214704T2 (el)
DK (1) DK0508756T3 (el)
ES (1) ES2094290T3 (el)
GR (1) GR3021892T3 (el)
IE (1) IE75709B1 (el)
NZ (1) NZ242271A (el)
TW (1) TW212761B (el)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19701264A1 (de) * 1997-01-16 1998-07-23 Kief Lizenz Verwertungsgesells Heilmittel, enthaltend Betasitosterin und/oder Phytosterol/Betasitosteringemische
IL153378A0 (en) * 2000-07-18 2003-07-06 Bone Care Internat Inc STABILIZED 1alpha-HYDROXY VITAMIN D
CN1449289A (zh) * 2000-08-30 2003-10-15 中外制药株式会社 Oct制剂
US20030191093A1 (en) * 2001-12-03 2003-10-09 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
EP3047847A1 (en) * 2005-10-12 2016-07-27 OPKO Renal, LLC Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency
DK1993559T3 (en) 2006-02-03 2016-10-03 Opko Renal Llc Treatment of vitamin D deficiency and MALFUNCTION with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3
ES2670029T3 (es) 2006-06-21 2018-05-29 Opko Ireland Global Holdings, Ltd. Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D
DK2481400T3 (da) 2007-04-25 2014-09-29 Opko Ip Holdings Ii Inc Orale præparater med kontrolleret frigivelse omfattende en vitamin D-forbindelse og en voksagtig bærer
KR101495578B1 (ko) 2007-04-25 2015-02-25 사이토크로마 인코포레이티드 비타민 ｄ 부족 및 결핍의 치료 방법
EP3225243A1 (en) 2007-04-25 2017-10-04 Opko Renal, LLC Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
CA2684778C (en) 2007-04-25 2017-09-05 Cytochroma Inc. Methods and compounds for vitamin d therapy
ES2954932T3 (es) 2008-04-02 2023-11-27 Eirgen Pharma Ltd Métodos, composiciones, usos y kits útiles para la deficiencia de vitamina D y trastornos relacionados
CN105796530A (zh) 2010-03-29 2016-07-27 赛特克罗公司 用于降低甲状旁腺水平的方法和组合物
CA2698160C (en) * 2010-03-30 2017-07-25 Alphora Research Inc. Stabilized doxercalciferol and process for manufacturing the same
EP2468265A3 (en) * 2010-12-04 2013-01-02 DEEF Pharmaceutical Industries Co. Homogeneous preparations containing vitamin D
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
IL290855B2 (en) 2016-03-28 2024-06-01 Eirgen Pharma Ltd Treatment methods using vitamin D
JP7085105B2 (ja) * 2016-11-10 2022-06-16 日産化学株式会社 ビタミンｄ３誘導体の製剤
DE202019005769U1 (de) * 2018-08-31 2022-01-13 Eirgen Pharma Ltd. Pädiatrische Darreichungsformen von Vitamin D und Verwendung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59155309A (ja) * 1983-02-22 1984-09-04 Teijin Ltd 活性型ビタミンｄ↓３類組成物
JPS6217A (ja) * 1985-02-14 1987-01-06 Chugai Pharmaceut Co Ltd 安定な活性型ビタミンｄ３類製剤
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
JP2525478B2 (ja) * 1989-03-01 1996-08-21 帝人株式会社 安定性の改良された活性型ビタミンｄ▲下３▼類固型製剤
JPH04198129A (ja) * 1990-11-28 1992-07-17 Sumitomo Pharmaceut Co Ltd 活性型ビタミンｄ↓３類含有組成物

Also Published As

Publication number Publication date
CA2065603C (en) 2007-04-03
IE921126A1 (en) 1992-10-21
CA2065603A1 (en) 1992-10-10
TW212761B (el) 1993-09-11
DE69214704T2 (de) 1997-04-17
DK0508756T3 (da) 1997-03-24
EP0508756B1 (en) 1996-10-23
JPH05279260A (ja) 1993-10-26
EP0508756A1 (en) 1992-10-14
ATE144424T1 (de) 1996-11-15
ES2094290T3 (es) 1997-01-16
IE75709B1 (en) 1997-09-10
US5487900A (en) 1996-01-30
KR920019346A (ko) 1992-11-19
DE69214704D1 (de) 1996-11-28
AU1480492A (en) 1992-10-15
AU649802B2 (en) 1994-06-02
KR100231633B1 (ko) 1999-11-15
NZ242271A (en) 1993-10-26

Similar Documents

Publication Publication Date Title
GR3021892T3 (en) Stabilized vitamin D preparation
CA2027592A1 (en) Solid pharmaceutical preparations of active form of vitamin d_ of improved stability
AU6542986A (en) Pyridyl-methylthio substituted benzimidazoles
EP0519428A3 (en) Cyclodextrin composition
AU4740893A (en) Stabilized pharmaceutical compositions containing derivatives of vitamins D2 and D3
AU3317589A (en) Antacid compositions with prolonged gastric residence time
ES2171498T3 (es) Composicion farmaceutica solida que comprende un excipiente capaz de juntarse con el agua.
EP0598337A3 (en) Medicinal compositions containing a drug, a cross-linked polymer, an oil, and a surfactant.
ATE50980T1 (de) Polymer-stabilisierende verbindungen und diese enthaltende stabilisierte polymerzusammensetzungen.
ES2076358T3 (es) Granulados con elevado contenido de ibuprofeno.
SG46307A1 (en) New pyrazine derivatives the preparation and use thereof
HUT66234A (en) Process to prepare 4,13-dioxabicyclo(8.2.1)-tridecenon-derivatives and pharmaceutical compositions containing them
AU7043187A (en) Dispersible composition of ceramic solid and a dispersant
SE8600658D0 (sv) Novel composition of matter
CA2315685A1 (en) Molecular dispersion composition with enhanced bioavailability
AU629445B2 (en) Improvements in or relating to topical compositions containing 1 alpha 25-dihydroxycholecalciferol
EP0533516A3 (fr) Nouveaux composés amidiques des 1-(alcoxybenzyl) pipérazines, leurs procédés de préparation, et les compositions pharmaceutiques qui les contiennent
GR3019751T3 (en) Sustained release formulations of acetazolamide
IL102880A0 (en) Hexahydrobenzo(f)quinolinones
AU5140490A (en) Use of mixed micelles
DK0384416T3 (da) Farmaceutisk sammensætning indeholdende hydantoinderivat
TH6020B (th) สูตรผสมเมนาไดโอนไบซัลโฟท์ที่ได้ทำให้เสถียร และการเตรียมสูตรผสมเหล่านี้